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Abstract Uptake of cholesterol from peripheral cells by
nascent small HDL circulating in plasma is necessary to pre-
vent atherosclerosis. This process, termed reverse cholesterol
transport, produces larger cholesterol-rich HDL that trans-
fers its cholesterol to the liver facilitating excretion. Most
HDL in plasma is cholesterol-rich. We demonstrate that
treating plasma with a novel selective delipidation procedure
converts large to small HDL [HDL-selectively delipidated
(HDL-sdl)]. HDL-sdl contains several cholesterol-depleted
species resembling small a, preb-1, and other preb forms.
Selective delipidation markedly increases efficacy of plasma
to stimulate ABCA1-mediated cholesterol transfer from
monocytic cells to HDL. Plasma from African Green mon-
keys underwent selective HDL delipidation. The delipidated
plasma was reinfused into five monkeys. Preb-1-like HDL
had a plasma residence time of 8 6 6 h and was converted
entirely to large a-HDL having residence times of 13–14 h.
Small a-HDL was converted entirely to large a-HDL. These
findings suggest that selective HDL delipidation activates re-
verse cholesterol transport, in vivo and in vitro. Treatment
with delipidated plasma tended to reduce diet-induced aortic
atherosclerosis in monkeys measured by intravascular ultra-
sound. These findings link the conversion of small to large
HDL, in vivo, to improvement in atherosclerosis.—Sacks, F. M.,
L. L. Rudel, A. Conner, H. Akeefe, G. Kostner, T. Baki, G.
Rothblat, M. de la Llera-Moya, B. Asztalos, T. Perlman, C.
Zheng, P. Alaupovic, J-A. B. Maltais, and H. B. Brewer. Se-
lective delipidation of plasma HDL enhances reverse cho-
lesterol transport in vivo. J. Lipid Res. 2009. 50: 894–907.
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In 1951, it was reported that a minor component of the
plasma lipoproteins was paradoxically reduced in patients
who had coronary heart disease (CHD), in contrast to the
bulk of plasma lipoproteins that were notably increased
(1). Nine years later, the first prospective studies confirmed
that a low plasma HDL cholesterol concentration is a pre-
dictor of CHD (2), as have subsequent studies of large popu-
lations (3, 4). A low plasma HDL cholesterol concentration
is also a predictor of stroke (5). The relation between HDL
cholesterol and CHD is strong and consistent among men
and women, young and old, and in those with low or high
LDL cholesterol concentrations (6); and the influence on
HDL cholesterol on risk of CHD persists even during treat-
ment with statins at typical (7) or high doses (8). These
findings support the theory that HDL is a component of
the lipoprotein system that not only protects against the
atherogenic actions of VLDL and LDL, but also may be es-
sential to prevent atherosclerosis even when plasma LDL
cholesterol concentration is very low.
HDL transports cholesterol from peripheral tissues, in-
cluding arterial wall, to the liver directly or by transferring
cholesterol to VLDL and LDL in plasma, which eventually
deliver much of their cholesterol to the liver (9, 10). The
liver can then channel the excess cholesterol for excretion
into the bile. This complex process is called reverse choles-
terol transport. The step that initiates cholesterol removal
from macrophages, the predominant cholesterol-loaded
cell type in atherosclerosis, is activation by HDL of choles-
terol transporters. Although several cholesterol transporters
exist in macrophages and can move cholesterol from inside
the cell to HDL, one of them, ABCA1, is required to prevent
cholesterol overloading and atherosclerosis. People who
lack ABCA1 have abnormal HDL with very low cholesterol
content, very low HDL cholesterol concentrations, and suf-
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fer atherosclerosis as early and severely as people with fa-
milial hypercholesterolemia (11, 12). People with partial
loss of ABCA1 have less severely reduced HDL cholesterol
concentration (13). Variation in expression of human
ABCA1 in mice predictably affects HDL cholesterol con-
centrations and atherosclerosis (14, 15).
ABCA1 is activated by preb-1HDL (16), a flat disk-like
complex of phospholipid and a protein, apolipoprotein
A-I (17–19). Preb-1HDL has very little cholesterol (19–21),
comprises approximately 5–10% of apoA-I in HDL, and is
the main type of HDL that the liver secretes into plasma.
After acquiring cholesterol, preb-1HDL enlarges, takes a
spherical shape, and becomes part of the major type of cir-
culating HDL, called a-HDL (17, 20). a-HDL exists in hu-
man plasma in several semidiscrete sizes called a- 4,3,2, and
1 from small to large (19). Small a-HDL may enlarge by
acquiring more cholesterol from cells by other transport-
ers and receptors (22–25). Alpha HDL may be catabolized
directly by the liver, kidney, and other steroidogenic tissues;
deliver some of its cholesterol to the liver assisted by several
enzymes and receptors on the surface of the hepatocyte; or
transfer some of its cholesterol to VLDL and LDL, which
ultimately are removed from circulation by hepatic LDL
receptors (26–28). Effective reverse cholesterol transport
requires a continual supply of cholesterol-poor HDL enter-
ing the circulation. In animal models of atherosclerosis
and in humans with coronary atherosclerosis, giving intra-
venously complexes of apoA-I and phospholipid, similar to
preb-1 HDL, reduced atherosclerosis (29–33). However,
there are obstacles, theoretical and practical, to using
preb-1HDL as a therapy. Conversion of preb-1 to a-HDL,
an essential step in reverse cholesterol transport and the
theoretical rationale for HDL treatment, has not been di-
rectly observed or quantified in a primate, in vivo. ApoA-I
is too large to manufacture in sufficient quantities for treat-
ment, and the safety of intravenously infusing nonautolo-
gous apoA-I has not been established.
The study asked whether cholesterol-depleted HDL could
be generated in human and nonhuman primate plasma by
selective delipidation of the predominant, cholesterol-rich
a-HDL; whether it is active in cholesterol removal from
cholesterol-loaded cells by ABCA1; whether it can be con-
verted to large a-HDL in vivo; and whether it could reduce
aortic atherosclerosis in a nonhuman primate model of
diet-induced atherosclerosis. If the results were positive, se-
lective HDL delipidation would have potential to be a treat-
ment for atherosclerosis.
METHODS
Selective HDL delipidation
Citrated plasma was purchased from local blood banks. Several
hundred permutations of delipidation reagents and reagent com-
binations, and of plasma to delipidation reagent ratios, were
screened to identify the parameters for selectively delipidating
HDL in plasma. Forward selection criteria included removal of
cholesterol from HDL, no change in LDL cholesterol content
or size, and stability of lipoproteins in delipidated plasma. Plasma
was mixed with delipidation reagents, sevoflourane (a nonflam-
mable fluorinated ether) and n-butanol. After mixing, plasma
and delipidation reagents were bulk separated by gravity and the
delipidated plasma was passed through a charcoal column to re-
move residual delipidation reagents. The plasma was tested using
a validated gas chromatographic head space method to ensure
that residual delipidation reagents were removed before infusion.
Delipidated plasma was tested using gas chromatography opti-
mized for the detection of residual delipidation reagents. In all de-
lipidation studies of monkey and human plasma, residual levels of
the delipidation reagents were below the combined limit of detec-
tion, 1.56 ppm, except in one case with human plasma in which
the n-butanol was 0.00 ppm and the sevoflurane was 3.40 ppm.
Conservative acceptance limits established for a recently con-
cluded human clinical trial were <20 ppm (mg/L) n-butanol
and <35 ppm (mg/L) fluorinated ether.
Lipid, lipoprotein, apolipoprotein, and
enzyme measurements
Lipids and apolipoproteins were measured in plasma before
and after delipidation. Cholesterol, nonesterifed cholesterol, phos-
pholipid, and triglycerides were measured by enzymatic colorime-
try (Wako Chemicals USA, Inc., Richmond, VA). HDL cholesterol
was measured by precipitation and enzymatic assay (Wako). LDL
cholesterol was measured by direct assay (Wako). VLDL choles-
terol was computed by subtracting LDL and HDL cholesterol
from the total. ApoB and apoA-I were measured by turbidimetric
immunoassay using goat anti-human apoB or apoA-I (Wako). Lipo-
protein size and composition were studied by gel permeation chro-
matography. Plasma or delipidated plasma was applied to Superose
6 column (Amersham Pharmacia), and the indicated fractions
were analyzed for cholesterol, phospholipids, and apoA-I.
ApoB lipoproteins may be TG-rich, mostly containing apoC-III
or cholesterol-rich that mostly do not contain apoC-III. These
types were separated by a combination of immunoprecipitation
and immunoaffinity chromatography (34). ApoC-III was measured
by electroimmunoassay in plasma, in plasma after precipitation of
apoB-containing lipoproteins (VLDL, LDL) by heparin and man-
ganese chloride, and in the precipitate (34).
LCAT and cholestryl ester transfer protein (CETP) activities
were determined as described previously (35, 36). The principle
of this method is that the increase in cholesterol ester measured
in plasma incubated in vitro as a result of LCAT activity is associ-
ated with an equivalent molar decrease in free cholesterol. The
rate of CETP-mediated transfer of cholesterol ester from HDL to
VLDL and LDL is then the difference between the rate of decrease
in free cholesterol in whole plasma, and the rate of increase of cho-
lesterol ester in HDL, as a function of time. This assay provides
unique information on the interplay between LCAT and CETP re-
actions by measuring total cholesterol and free cholesterol in total
plasma and in apoB-depleted plasma at two time-points.
HDL subtypes produced by selective plasma delipidation,
measured by two-dimensional gel electrophoresis
Samples for two-dimensional gel analysis were frozen at 270°C
and shipped on dry ice to Tufts University Boston (Boston, MA)
for native two-dimensional gel electrophoresis, immunoblotting
and image analysis. Each sample received was separated on agarose
gel by charge into preb-, a-, and prea-mobility particles and on na-
tive 3–35% concave gradient polyacrylamide gel by size (5.6 nm to
17.1 nm). Pharmacia High Molecular Weight standard proteins
were run in each gel to calculate particle size. Samples were also
separated on native 3–16% linear gradient gel in the second di-
mension to resolve lipid-free apoA-I from preb HDL. Gels were
electro-transferred to nitrocellulose membranes and immuno-
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probed for apoA-I with mono-specific polyclonal primary and I125
labeled secondary antibodies. Membranes were scanned in a fluoro
imager (Molecular Dynamics, Sunnyvale, CA) in X-ray mode. The
percent distribution of the signals for each particle was determined
by image-analysis using ImmageQuant software. ApoA-I contents of
the particles were calculated by multiplying the percentiles by the
plasma apoA-I level. An in-house reference plasma sample was run
with each batch of samples under the same conditions as a control.
Metabolism in mice of LDL from selectively delipidated
human plasma
A conventional mouse model of LDL metabolism was used to
determine whether selective delipidation affects the clearance of
LDL from plasma, a process dependent upon normal recognition
of apoB in LDL by LDL receptors, mainly on the liver. If selective
delipidation affects the LDL receptor binding region of apoB, or
extensively denatures apoB, then clearance from plasma of LDL
would be altered. LDL was prepared from 150 ml fresh human
citrated plasma obtained from the blood bank at Medical Univer-
sity of Graz, Austria. The lipid concentrations for the plasma were
total triglycerides 47 mg/dl, total cholesterol 171 mg/dl, HDL-
cholesterol 54 mg/dl, and LDL-cholesterol 108 mg/dl. LDL was
prepared by ultracentrifugation within the density range of
1.027–1.063 g/ml. LDL was purified further by density gradient
ultracentrifugation, and a narrow band at the appropriate position
for LDL protein was harvested. EDTA, 1 mg/ml, was added. LDL,
8 mg protein, was iodinated according to the N-Br succinimide
method using 1.5 mCi each of either 125I or 131I . Normal human
plasma was spiked with either 125I or 131I LDL. The plasma con-
taining 125I LDL was delipidated with the selective delipidation
method. Recovery of 125I LDL from the delipidated plasma was
complete, 102%. Two groups of five mice were each injected with
a mixture of the two plasmas. Decay of radioactivity of the LDL in
blood after injection was used to quantify the removal and catab-
olism of LDL from delipidated plasma (125I labeled) compared
with that of LDL from undelipidated plasma (131I labeled). Plasma
half-lives for LDL from native and delipidated plasma were com-
puted from the disappearance curves for radioactivity (GraphPad
Prism) and compared by 2-sample t-test. LDL was also prepared
from delipidated and undelipidated plasma by ultracentrifuga-
tion and applied to a Biogel A-15M column and eluted in phos-
phate buffered saline at a flow rate of 0.6 cm/h to determine the
effect of the delipidation procedure on the size of LDL.
Cholesterol efflux stimulated in cells by selective
plasma delipidation
Release of radiolabeled cellular cholesterol to isolated acceptors
(e.g., HDL subtypes), or whole serum or plasma was measured at
Childrenʼs Hospital of Philadelphia as previously described (37).
Fu5AH cells were maintained in MEM supplemented with 5%
CS and antibiotics. J774 macrophages were maintained in RPMI
supplemented with 10% FBS and antibiotics. For efflux experi-
ments 350,000 cells per well were plated in 24-well plates using
0.5 ml of the corresponding growth medium. After 24 h, the growth
medium was replaced with 0.5 ml of labeling medium containing
2 mCi[3H]cholesterol/ml and 2 mg/ml of the ACAT inhibitor
CP113, 818, and the cells were incubated in this medium for an-
other day. Fu5AH cells were labeled with radioactive cholesterol
in MEM containing 0.5% CS and J774 cells were labeled using
RPMI containing 1% FBS.
SRB1 mediated cell cholesterol efflux was measured as the
fraction of radioactive cholesterol released from Fu5AH cells to
0.2 ml/well of MEM-HEPES containing the test samples as the
majority of the cholesterol efflux from these cells is mediated by
SRB1. The test samples of HDL or delipidated HDL were loaded
based on a concentration of 15 mg/ml apoA-I. J774 cells were also
incubated with 0.2ml/well of MEM-HEPES containing the test
samples, Internal control serum was added at 2% v/v in each ex-
periment. ABCA1 mediated efflux was measured as the difference
in release of radioactive cellular cholesterol to these media from
J774 control macrophages and J774 macrophages up-regulated
to express ABCA1 (ABCA1 efflux 5 FC efflux from up-regulated
cells minus FC efflux from control cells). To up-regulate ABCA1 in
J774 macrophages, one half of the wells plated with labeled J774
cells were incubated for 16–18 h with 0.5 ml/well of RPMI contain-
ing 0.2% BSA, 2 ug/ml CP113, 818 and 0.3 mM cpt-cAMP. Labeled
control J774 cells and Fu5AH cells were also incubated for 16–18 h
with the same medium without cpt-cAMP. Prior to addition of ef-
flux medium containing the samples to be tested, all cell monolay-
ers were gently washed once with 0.5 ml/well MEM supplemented
with 1% BSA and once with 0.5 ml/well MEM. All efflux assays
were incubated for 4 h at 37°C and done in triplicate. The fraction
of the total radiolabel incorporated into cell lipids released during
incubation with the test samples was measured as follows. Radio-
active cholesterol incorporated into cell lipids was extracted by in-
cubating a set of triplicate wells of Fu5AH, control J774 and
up-regulated J774 cells not exposed to the test serum (T0 cells),
overnight with 1 ml isopropanol/well. Total cellular cholesterol
label was measured by liquid scintillation counting in aliquots of
the isopropanol extracts after drying and resuspension in toluene.
Radioactive cholesterol released to test samples after incubation
with Fu5AH cells for 4 h or with control and up-regulated J774
cells for 4 h, was measured by scintillation counting of 100 ml ali-
quots of efflux medium that had been filtered through 0.45 mm-
multiscreen filtration plates. All efflux values were corrected by
subtracting the small amount of radioactive cholesterol released
from triplicate wells of Fu5AH, control and up-regulated J774 cells
incubated with serum-free medium.
HDL kinetics in monkeys treated with selectively
delipidated monkey plasma
Five monkeys were selected from a larger group of St. Kitts Afri-
can Green Monkeys (vervets) participating in a dietary fatty acid
study at Wake Forest University Medical Center, North Carolina.
This primate population, having been on a high-fat diet for 7 years,
had developed atherosclerosis, thus providing a model that was
genetically similar to man. The plasma used for the delipidation
was donor plasma from vervets stored at 220°C since collection.
The five recipient monkeys were chosen to be of the same ABO
blood group as the plasma donor animals with no irregular iso-
agglutinins. Research involving these animals was approved by the
Wake Forest University Animal Care and Use Committee and con-
formed to the Wake Forest NonHuman Primate Environmental
Enrichment Plan and Policies.
Donor vervet plasma was thawed in the refrigerator overnight.
Thawed plasma was pooled, and cryoprecipitate removed by cen-
trifugation (3,500 rpm for 10 min). The vervet plasma was de-
lipidated using the selective delipidation method under aseptic
conditions as described above and checked for residual delipida-
tion reagents via gas chromatography prior to infusion.
Delipidated plasma was divided into aliquots by volume to pro-
vide the appropriate target dose of apoA-I per monkey based on
monkey weight. The monkeys were given one infusion IVof selec-
tively delipidated vervet plasma. The target dosage per recipient
monkey was 15-30 mg/kg body weight of apoA-I as measured with
vervet specific apoA-I antibodies (38). The target dosage was cho-
sen based on the effective dosages reported in prior atherosclerosis
regression studies in animals (29–32), and in humans (33). Animal
weights ranged from 6.3 to 8.6 kg, typical for this population of
vervets. Plasma was infused at room temperature at a flow rate
up to 3 ml/min depending on the tolerance of the animal. The
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duration time of infusion ranged from 61 to 84 min. The volume
of delipidated plasma given ranged from 95 to 135 ml. The dose of
apoA-I delivered per animal was 22 to 23 mg/kg. Diazepam and
ketamine were used for anesthesia for the infusion procedure,
and ketamine was given periodically for sedation for blood sample
collections. Clinical and physiological parameters were measured
or monitored. The infusions were well tolerated by the monkeys.
Plasma samples were taken before the infusion, during the in-
fusion, and periodically after the infusion at intervals up to 96 h
(Fig. 1). HDL cholesterol, total apoA-I, preb-1,other preb, and
a-HDL particles were measured as described previously. The con-
centrations of apoA-I in preb-1-like, a-3, a-2, and a-1 HDL at the
sampling times after infusion were modeled by SAAM II compart-
mental software by Drs. Zheng and Sacks. An HDL migrating to
the preb-1 position and an HDL migrating to a nearly position
not found in native plasma were combined and called “preb-1-like”
HDL. In addition, a-3 and a-4 HDL were combined in this model
and called a-3. De novo secretion rates of apoA-I in small (preb-1-
like and a-3), medium (a-2), and large HDL (a-1) in vervets were
taken from the previous studies of the investigators (39). The final
model consisted of bolus inputs of preb-1-like, a-3, a-2, and a-1
HDL in the amounts contained in the infusion; conversion of
preb-1-like to a-3, a-2, and a-1; conversion of a-3 to a-2 and to
a1; conversion of a-2 to a1; and removal of a-2 and a-1 from plasma
(Fig. 2). Other pathways were tested including clearance from
plasma of preb-1-like and a-3 HDL, conversion of a-mobility par-
ticles to preb-1 HDL, and conversion of larger to smaller a HDL.
Pathways for which rate constants are zero or negligible were
eliminated. Data from each monkey were modeled separately.
Mean and SD of the rate constants, residence times, and half-lives
were computed.
Aortic atherosclerosis in monkeys
Twelve additional monkeys in the atherosclerosis study were
entered into a study of 12 weekly treatments of selectively delipid-
ated monkey plasma as described previously for the HDL kinetics
study. Intravascular ultrasound (IVUS) of the abdominal aorta
was performed before treatment was started and after the final
administration of delipidated plasma. The animals were anesthe-
tized, heparin (150–200 units) was given IV prior to catheter intro-
duction, and a small intravascular catheter sheath (2.6–3.0 French
or 0.87–1.00 mm) and guidewire were inserted in the right exter-
nal iliac artery. An IVUS catheter with transducer [Volcano™ Ther-
apeutics In-Vision Intravascular Ultrasound System (K031148) with
Volcano Therapeutics Eagle Eye™ 20 MHz Imaging Catheter
(K031346)] was advanced proximally and positioned in the aorta
above the renal arteries. Nitroglycerin (10–40 mcg per dose) was
injected into the aorta to reduce vasoconstriction. The catheter
was then retracted by motor at a constant speed of 0.5 mm/sec
from this starting point through the right common iliac artery to
the sheath. Ultrasonic images were collected with radiofrequency
backscatter triggered by the heart beat of the animal. An image was
taken every 0.35 s or 0.18 mm on average. The catheter was re-
moved and the artery sutured. The animals were monitored until
fully awake and responsive. The same procedure was followed for
pre and posttreatment measurements.
Lesions were located and mapped individually in each frame
by manual planimetry to delineate the borders of the lumen and
the external elastic lamina.The primary IVUS analysis (planimetry
and lesion identification) was conducted by Volcano Therapeutics,
Rancho Cordova. Personnel who performed the manual plani-
metry were blinded to the identity of the monkey and whether
the images were from the pre or posttreatment measurement. After
planimetry, images were reassembled according to animal and tem-
poral sequence. Lesions on the pre- and posttreatment studies
were matched.
Atheroma area was calculated in each frame by subtracting the
luminal area from the area bounded by the external elastic mem-
brane (33, 40). Atheroma area includes the intimal and medial
layers. Atheroma volume of each lesion was calculated by multiply-
ing the mean atheroma area of the images by its length. Percent
atheroma volume, also called atheroma or plaque burden, was
computed by dividing the sum of all the atheroma areas by the
sum of all of the areas bounded by the external elastic membrane.
Changes in atheroma volume and percent atheroma volume are
considered to be outcome measures of choice for measuring the
effect of a treatment on human coronary arteries using IVUS (40).
All lesions that were present in both pre- and posttreatment images
were included. We chose this discrete lesion method, analogous to
the “most-diseased subsegment” analysis that is often used in the
vascular imaging field, because it emphasizes effects on the most
diseased areas of the vessel. Because the focal “IVUS-identifiable”
lesions were variable in length, all lesions were normalized to le-
sion length. The lesion was the unit of observation in the statisti-
cal analysis.
RESULTS
Selective HDL delipidation of human plasma
In early benchtop development, selective HDL delipida-
tion reduced HDL cholesterol concentration in human
plasma from 42 mg/dl to 10 mg/dl, a 77% reduction
(N 5 51 samples, P , 0.0001) (Table 1). LDL choles-
terol was not affected. VLDL cholesterol increased from
22 mg/dl to 34 mg/dl (P , 0.0003). Plasma total triglycer-
ides decreased by 14%, phospholipids by 15%, and unes-
terified cholesterol by 10%.
Selective delipidation affected HDL size and composition
as shown by gel permeation chromatography (Fig. 3). HDL-
Fig. 1. Design of HDL kinetics study in African Green Monkeys (vervets). Vervet plasma underwent selective
HDL delipidation and was infused into five recipient vervets. Arrows depict times of blood sampling.
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sdl was depleted of cholesterol, and the size of HDL-sdl was
smaller than in native plasma, as shown by the positions of
the HDL phospholipid and apolipoprotein A-I peaks. The
HDL-sdl phospholipid and apoA-I peaks were slightly re-
duced in magnitude compared with native plasma. The
position, width, and shape of the VLDL peak were not af-
fected by selective delipidation. The magnitude of the
VLDL cholesterol peak was increased. The position of the
LDL peak was also unchanged. Apolipoprotein C-III
concentration in HDL was decreased by 39% from 6.1 6
1.9 to 3.7 6 0.2 mg/dl (N 5 5 normolipidemic samples,
P , 0.05).
Removal of cholesterol mass from HDL was strictly pro-
portional to the concentration of HDL cholesterol in plasma
before the procedure (Fig. 4, upper panel). Percent re-
moval of cholesterol from HDL was constant over the range
of HDL cholesterol concentrations (Fig. 4, lower panel).
Thus, the selective delipidation method has similar ef-
fectiveness for plasma with high or low HDL cholesterol
concentrations, and across a wide range of plasma total cho-
lesterol (50–650 mg/dl) or triglyceride (40–700 mg/dl)
concentrations (data not shown).
Selective delipidation markedly decreased a-HDL from
93 6 3% to 21 6 6%, and produced a mixture of semidis-
crete species on the 2-d gels, one approximately in the loca-
tion of native preb-1; another near preb-1 but not present
in native plasma, preb-x; and the smallest type of a, a-4. In
native plasma, preb-1 comprised 6 6 3% of total HDL
apoA-I immunoreactivity. HDL-sdl was 79 6 6% preb-1-like
(N 5 6 samples, Fig. 5). The total apoA-I concentration of
the samples before delipidation was 112 mg/dl, and 91%
was recovered after the procedure. Sham delipidation that
included all steps in the delipidation procedure but with-
out the delipidation reagents added produced no changes
(data not shown). HDL-sdl has little large- and medium-
size a-1 and a-2 HDL that is predominant in native plasma.
LCAT activity is retained in selectively delipidated plasma,
whereas CETP activity is markedly reduced by 74% (P ,
0.003) (N 5 6 samples, Table 1).
TABLE 1. Effect of selective HDL delipidation on plasma lipids,
apolipoproteins, and LCAT and cholestryl ester transfer protein
(CETP) of human plasma
Pretreatment
(SD)
Posttreatment
(SD) P value
Total cholesterol 159.(24) 141.(22) ,0.0002
Unesterified cholesterol 41.(7) 37.(8) ,0.001
Total triglyceride 164.(121) 141.(108) 0.3
Total phospholipid 186.(26) 158.(27) ,0.0001
HDL-cholesterol 42.(9) 10.(6) ,0.0001
LDL-cholesterol 95.(21) 98.(20) 0.598
VLDL-cholesterol 22.(16) 34.(17) ,0.0003
ApoA-I 109.(14) 81.(15) ,0.0001
ApoB 72.(14) 66.(13) ,0.03
LCATa 7.4 (3.0) 7.9 (3.0) 0.42
CETPa 518.(182) 131.(35) ,0.003
N 5 51. Units 5 (mg/dl) except LCAT (mg/ml/h) and CETP
(nmol/ml/h).
a N 5 6.
Fig. 2. Compartmental model for metabolism of preb-1 and a-HDL in African GreenMonkeys. Compartment 1:
plasma preb-1 apoA-I. Compartment 11: noncirculating preb-1 apoA-I. Compartment 2: plasma a-3 apoA-I. Com-
partment 21: Noncirculating a-3 apoA-I. Compartment 3: plasma a-2 apoA-I. Compartment 4: plasma a-1 apoA-I.
Compartments 5 and 6: delay compartments. Selectively delipidated vervet plasma containing preb-1-like, a-3, a-2,
and a-1 HDL was infused into five recipient vervets. Noncirculating compartments 11 and 21 are required for
preb-1 and a-3 HDL because the amount of injected donor apoA-I in these two fractions was significantly higher
than the increment in plasmapreb-1 and a-3HDL observed in recipientmonkeys (i.e., only a fraction of injected
apoA-I appears in plasma immediately after infusion and the rest appears after a delay). The residence times for
the noncirculating compartments of preb-1 and a-3 HDL are the reciprocals of the rate constants k(1,11) and
k(2,21), respectively. Data represented are mean 6 SEM from modeling five monkeys individually. k, rate con-
stants (pools/day); d, delay compartment; % 5 flux distributions.
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ApoB lipoproteins (VLDL, LDL) are composed of TG-
rich lipoproteins, usually containing apoC-III and one or
more of several other apolipoproteins such as apoC-I, C-
II, E, A-II, and D, and called “LpBc;” and cholesterol-rich
lipoproteins that do not have apoC-III and have smaller
amounts of the other apolipoproteins, called “LpB” (34).
Selective HDL delipidation did not affect the apoB concen-
trations or proportions of these two types of lipoproteins:
LpBc 20 6 4 vs. 21 6 5; LpB 50 6 10 vs. 44 6 8 mg/dl
(mean 6 SD) N 5 5 normolipidemic plasma samples.
ApoC-III in apoB lipoproteins was also not affected: 4.9 6
1.2 vs. 4.6 6 1.3 mg/dl.
Metabolism in mice of LDL from selectively delipidated
human plasma
LDL from human plasma that had been selectively de-
lipidated was compared with LDL from native plasma. Selec-
tive delipidation had no effect on the size of LDL (Fig. 6).
The plasma half-life was 4.1 6 0.4 (SD) h for LDL from de-
lipidated plasma compared with 3.1 6 0.2 h for LDL from
native plasma (P , 0.01).
Cholesterol efflux stimulated in cells by selective
plasma delipidation
Cholesterol efflux via ABCA1 transporters was improved
by the selectively delipidated plasmas for all 16 samples.
Compared with sham-processed plasma (no delipidation
reagents), selectively delipidated plasma increased ABCA1
specific cholesterol efflux by 7.1 6 1.8 (SEM) fold (Fig. 7).
The median increase was 4-fold, and the range was 1.3 to
27. In contrast, selective delipidation slightly decreased
cholesterol efflux via SRB1. Selectively delipidated plasma
effluxes cholesterol as well as lipid poor apoA-I, and out-
performs HDL-3, a small dense fraction of HDL that con-
tains a- and preb-1 HDL subtypes.
HDL kinetics in monkeys treated with selectively
delipidated monkey plasma
Selective delipidation of pooled donor monkey plasma
reduced a-1 from 21% to 1% and a-2 HDL from 35% to
7%, and increased a-3 HDL from 29% to 58% and preb-
like HDL from 15% to 36%. The kinetic behavior of the
HDL-sdl particle types is shown for the five monkeys
(Fig. 8). The infusion of HDL-sdl plasma took approxi-
mately 50 min. When the infusion was completed, the aver-
age pool size of preb-1-like particles had increased by 60 mg
apoA-I, representing a 2.1-fold increase over baseline. Sub-
sequent reduction in preb-1-like HDL concentration was bi-
phasic, consisting of a rapid initial phase and a slower later
phase. Reciprocal changes occurred in a-1 and a-2 HDL,
compared with preb-1-like HDL. Alpha 1 and 2 HDL con-
centrations decreased initially during the infusion, reflecting
dilution of the monkeysʼ plasma compartment by the se-
lectively delipidated donor plasma having low a-1 and a-2
Fig. 3. Effect on lipoprotein size and composition of selective HDL delipidation. Size exclusion chromatography on Superose 6. Solid line:
native plasma. Broken line: plasma after selective HDL delipidation. N 5 5 normal plasma pools.
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HDL concentration as a result of the delipidation process.
After infusion, a-1 and a-2 HDL increased rapidly for 2 h,
followed by a slow increase to 22 h to a new higher baseline
reflecting the amount of infused HDL that is converted to
these larger particles.
The kinetic behavior of plasma a-3 concentration, the
smallest a-mobility HDL particle in vervets, was intermediate
between preb-1-like HDL and a-1 and a-2 HDL (Fig. 8).
Alpha-3 particles initially increased during the infusion,
due to the high concentration of a-3 HDL in delipidated
plasma. After the infusion ended, a-3 HDL continued to
increase to 5 h, and then continuously declined to below
baseline at 96 h. Thus, the kinetic pattern after the infusion,
a decrease in preb-1 HDL, an interim increase in a-3 HDL,
and a later increase in a-1 and a-2 HDL depicts the reverse
cholesterol transport process.
Metabolism of HDL was quantified by kinetic modeling
of the apoA-I mass-time curves of preb-1-like, a-3, a-2, and
a-1 HDL (Fig. 2). The concentrations after infusion indi-
cated immediate and delayed appearance of preb-1-like
and a-3 HDL. The delayed appearance required initial
noncirculating pools of preb-1-like and a-mobility particles
that later entered the circulation as preb-1-like or a HDL,
respectively. Clearance from plasma of the noncirculat-
ing pools was evaluated and found not to fit the data.
The data required that all injected preb-1-like HDL is con-
verted to a HDL, either to the smallest a-mobility HDL,
a-3, or directly to the larger a-mobility HDL, a-2 and a-
1. Conversion of preb-1-like to any of these a-types re-
quired a delay compartment with a delay time (mean 6
SEM) of 0.56 6 0.4 h, and conversion of a-3 to a-2 or
a-1 HDL involved a delay compartment with mean delay
Fig. 4. Efficacy of selective HDL delipidation in 51 human plasma samples. A: mass of cholesterol removed
from HDL is proportional to the plasma HDL cholesterol concentration. B: percent of cholesterol removed
from HDL is constant across the range of HDL cholesterol concentrations.
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time of 0.92 6 0.4 h. The delay times from preb-1-like and
a-3 compartments were not significantly different. Thus,
HDL left the circulation as a-1 or a-2 particles, which
did not appear to be converted to one another. Conver-
sion pathways of larger to smaller HDL were tested, rep-
resenting selective cholesterol uptake by the liver. The
model fitting returned rate constants of zero for these
pathways. Thus they were not included in the final model
shown. Plasma residence times of the particles were simi-
lar, 13–14 h. The average coefficients of variation for the
fractional catabolic rates of the HDL types after successful
model fitting of the data for each monkey were 17% for
preb-1-like (k[5,1]), 15% for a-3 (k[6,2]), 24% for a-2
(k[0,3]), and 38% for a-1 (k[0,4]). Sensitivity analysis was
performed using in the model only an early period after
infusion up to 9 h when concentrations were changing rap-
idly or a later period from 9 h to 95 h when concentrations
were changing gradually. The final model and parameter
estimates in the time-restricted analyses were similar to
those of the full 95 h time period.
Aortic atherosclerosis in monkeys treated with selective
HDL delipidation
Twelve monkeys received a pretreatment IVUS study
and began weekly treatment with selectively delipidated
monkey plasma. Eleven monkeys completed the 12 treat-
ments, and one died after the second treatment for reasons
unrelated to the study. Matched pairs of lesions on pre-
and posttreatment IVUS studies were identified in 6 of
the 11 monkeys. The 6 monkeys had a total of 13 pairs
of lesions: 4 lesions in 1 monkey, 2 lesions in 4 monkeys,
and 1 lesion in 1 monkey.
Fig. 5. Selective HDL delipidation of human plasma produces a large shift in HDL types from a to preb HDL, demonstrated by native two-
dimensional gel electrophoresis. A: The upper left panel “Human HDL-fingerprint” represents the apoA-I containing (light gray) and apoA-
I:A-II containing (dark gray) HDL subpopulations in normolipidemic healthy human subjects in previous studies (16, 19). The asterisk
represents the position of human serum albumin, which marks the a-front. The larger a- and prea-mobility HDL (i.e., a-1, a-2, are lipid-rich
spherical particles); the smaller a-3, a-4 HDL are lipid-poor discs or transitional particles. Preb-2 consists of large, but lipid-poor discoidal
particles; preb-1 consists of small, lipid-poor discs. Preb-x represents the in-vitro shedding of lipid-poor apoA-I from larger HDL particles
caused by the selective delipidation procedure. Lipid content and shape of these bands were determined in previous studies (16, 19). The
remaining five panels show HDL in undelipidated plasma (left) and in selectively delipidated plasma from five normal human samples. “Pre” is
undelipidated plasma, and “Post” is that of the same plasma selectively delipidated. Samples were subjected to nondenaturing two-dimensional
gel electrophoresis and were immunolocalized with human apoA-I antibody. B: percentage of HDL apoA-I in preb and a HDL in six normal
subjects, five of whom are shown in the electrophoretograms in the upper panel. Mean6 SD. Front bars show undelipidated plasma, rear bars
show the same plasma sample after selective delipidation. Data determined by scanning the gels shown in the upper panel, and applying the
percentages to plasma total apoA-I. The minor prea 1, 2, and 3, 1–4% of total apoA-I is included with the respective a-HDL in predelipidated
samples and was not found postdelipidation. Preb-2, present only in predelipidated samples, 1% of total apoA-I, is not included. Preb-x is
included with the preb-1. The mean total apoA-I concentration of the samples before delipidation was 112 mg/dl, and 91% was recovered
after the procedure.
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Atheroma volume decreased significantly by 0.37 mm3
per mm lesion length, a 6.9 6 11.1% reduction (P 5 0.03)
(Table 2). Mean lesion length was unchanged, 11.3 6
10.0 vs. 11.5 6 9.9 mm; mean difference 0.2 6 2.9, P 5
0.9. Percent atheroma volume was 31.8 6 4.4% pretreat-
ment and 30.3 6 5.6% posttreatment, a decrease of 4.4%
that is not statistically significant (P 5 0.13).
DISCUSSION
The main findings of this study are: that treatment of
human or monkey plasma with a fluoroether-alcohol sol-
vent selectively delipidates HDL, converting cholesterol-
rich a-HDL to a mixture of cholesterol-poor small a, and
preb-like HDLs, termed HDL-sdl; that selectively delipid-
ated plasma has a greatly enhanced ability to stimulate
cholesterol efflux from cells by ABCA1 transporters; that
HDL-sdl produced by selective delipidation of monkey
plasma takes up cholesterol and is converted back to large
a-HDL in vivo during 96 h of circulating in the monkeys;
and that 12 weekly treatments with selectively delipidated
plasma tended to reduce atheroma volume in aortas of
monkeys who had diet-induced atherosclerosis. On aver-
age, delipidation of 1,100 ml human plasma would be
expected to produce 700 to 1,200 mg HDL-sdl, rich in
preb-1-like apoA-I, depending on the initial HDL apoA-I
concentration. These findings have implications for un-
derstanding HDL metabolism and for a potential treat-
ment of atherosclerosis and other vascular diseases.
LDL concentration, lipid composition, and size were not
affected, and its metabolism in mice was normal indicating
that the normal interaction of apoB with LDL receptors
that occurs in vivo is preserved. The concentrations of types
of apoB lipoproteins, TG-rich (LpBc) or cholesterol-rich
(LpB), were not affected. VLDL retained its size but its
cholesterol concentration increased after selective delipid-
ation. It is possible that some of the cholesterol extracted
from HDL by the delipidation was taken up by VLDL to
attain a thermodynamically more stable distribution, or
that CETP transferred cholesterol from HDL to VLDL
during the procedure. Some CETP activity was still de-
tected in delipidated plasma once the procedure was com-
plete. Because selective delipidation does not increase
VLDL cholesterol in the plasma of mice that do not have
CETP, we think this is evidence that there is a mild effect of
CETP in human plasma selective delipidation.
Selective delipidation of plasma left HDL with full func-
tion to activate ABCA1 in vitro. Selective delipidation re-
moved mainly cholesterol from HDL, preserving most
of the phospholipid. Selectively delipidated plasma was at
least as effective as lipid-free apoA-I in stimulating ABCA1-
mediated cholesterol efflux from cholesterol loaded
macrophage-like cells to HDL-sdl. In contrast, selectively
delipidated plasma did not enhance SRB1-mediated cho-
lesterol efflux, a mechanism for adding cholesterol to a-
HDL. The possible effect of selective delipidation on
ABCG1/4-mediated cholesterol efflux, another means of
adding cholesterol to a-HDL, was not studied. However,
the HDL kinetic findings in monkeys that a-3 HDL in de-
lipidated plasma is converted to a-1 and a-2 HDL, in vivo,
is consistent with the action of ABCG1/4 (23–25) or an-
other receptor or transporter with similar function.
Recently, it was shown that ABCA1 and ABCG1/4 can
act in a coordinated, sequential, or synergistic way to con-
vert preb-1 HDL to larger a-HDL particles (25). In essence,
Fig. 5.—Continued.
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ABCA1, when it fulfills its potential to deliver cholesterol to
a cholesterol-poor preb-1 HDL, “hands-off” the small a
HDL to ABCG1/4, which then adds cholesterol, converting
it to large a-1 and a-2 HDL. The kinetic findings in mon-
keys could represent in vivo evidence for this process due
to the fact that preb-1 HDL do not appear to be converted
to the next larger HDL type, a-3, but “jumped” one or two
steps, reappearing in plasma as a a-1 and a-2 HDL. These
pathways were needed for satisfactory fitting of the com-
partmental model to the data. In fact, the metabolic prod-
ucts of preb-1 HDL that appear in plasma include all three
a-HDLs; the percentage distribution from preb-1 HDL to
specific a-HDL types could reflect the availability of
ABCG1/4 or SRB1 relative to ABCA1 and could be influ-
enced by the excess amount of cellular cholesterol that
could drive the efflux system (41).
The kinetic findings suggest that none of the HDL in-
fused with selectively delipidated plasma is wasted (i.e.,
directly cleared) and not available for reverse cholesterol
transport. All preb-1-like HDL are converted to a-HDL,
and all a-3 HDL are converted to a-1 and a-2 HDL, and
these conversions occur through a sequestration compart-
ment, the “delay” pool. It is possible that the preb-1-like
and a-3 HDL, infused in large amounts relative to that in
native plasma, may have overloaded cellular cholesterol
transporters or receptors and caused preb-1 and a-3 parti-
cles to enter a sequestered space right after the infusion.
However, a substantial sequestration compartment was
found in a tracer study using small amounts of radio-
iodinated HDL (39). The sequestration compartment may
represent a normal docking mechanism for keeping small
HDL on the vascular endothelium, in the subintimal space
or even inside cholesterol-loaded cells (42) until cholesterol
transfer can occur, launching the a-1 and a-2 particles into
the circulation. This has an important physiological and po-
tential therapeutic meaning because nascent or infused
preb-1 and small a-HDL particles are efficiently and com-
pletely used for reverse cholesterol transport.
It is not possible to know how closely the kinetic findings
portray normal HDL metabolism or whether they are spe-
Fig. 6. Metabolism in mice of human LDL from selectively delipidated plasma. A: LDL elution profile by size exclusion chromatography on
Biogel A 15m. B: disappearance of radioactivity from LDL after injection into mice. Mean of five mice. Solid lines: 131I-LDL in native human
plasma. Broken lines: 125I-LDL in plasma treated with the selective HDL delipidation method. Disappearance curves for radioactivity
were fit by GraphPad Prism and half-lives computed. The mean (SD) for T1/2 for 131I-LDL was 3.1 6 0.2 h and for 125I-LDL was 4.1 6 0.4 h
(P , 0.01).
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Fig. 7. Cell cholesterol efflux caused by selectively delipidated plasma. A: ABCA1 mediated efflux. Ratio of
selectively delipidated or native plasma to sham delipidated plasma. Compared with sham processed plasma
(no delipidation reagents), selectively delipidated plasma increased ABCA1 specific cholesterol efflux by 7.1 6
1.8 (SEM) fold. The median increase was four-fold, and the range was 1.3 to 27. Control serum is an internal
standard and is added at 2% v/v, and results are typical. B: SRB1 mediated efflux. Ratio of selectively delipid-
ated to sham delipidated plasma. C: ABCA1 mediated efflux. Effects of selectively delipidated plasma, native
plasma (sham delipidated control), apoA-I, and HDL-3. Vertical axis units are efflux ratio of samples to purified
human apoA-I. N 5 16 plasma samples, mean 6 SEM.
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cific to the experimental conditions designed for therapy
(i.e., the HDL particles, termed HDL-sdl, produced by the
selective delipidation procedure). In vervets, kinetics of
radioiodinated a-HDL tracers with small, medium, or large
sizes share several key features with the present tracee ki-
netic study (39). Both studies found that conversion of
HDL particle types is unidirectional from small to large,
and that small HDL is quantitatively converted to large
HDL, none of it cleared directly. The radioiodinated HDL
study found that the conversion pathway from small to me-
dium or large HDL has a required noncirculating compart-
ment in which some small HDL is converted directly to large
HDL and some is converted to mediumHDL (39). This pro-
cess resembles the delay compartment used in the present
study in which a-3 HDL is converted to either a-2 or a-1
HDL. Human studies of HDL metabolism that used radio-
iodinated HDL also described two-pool models having
noncirculating and circulating components (43). The radio-
iodinated study determined that medium-size HDL is not
converted to large-size HDL, analogous to a-2 not being
converted to a-1 HDL in the present study. Finally, neither
the radioiodinated study nor the present study could iden-
tify conversion of larger to smaller HDL such as mediated
by SR-B1. Thus, the concordance of findings between these
two different studies of HDL metabolism in vervet monkeys
suggests that the present study may have identified some of
the normal pathways of HDL as it circulates in plasma.
In contrast to the concordant findings between tracer
and tracee studies with respect to the metabolic pathways
for plasma HDL metabolism, the present study estimated
lower residence times for a-HDL, 13–14 h, less than half
that found in the radioiodinated HDL study (39). A tracee
kinetic study of apoA-I infusion in humans showed that the
clearance rate from plasma of apoA-I increased with the
amounts of apoA-I given (44). The authors interpreted this
finding as direct first-pass clearance of infused apoA-I.
However, the present study found no evidence for rapid
clearance of infused apoA-I. It is possible that the large
amount of preb-1 and a-3 HDL infused in delipidated
plasma stimulated the rate of its own metabolism through
normal not aberrant pathways. A kinetic study of preb-1
and a-HDL in normal people, using primed-constant infu-
sion of trideuterated leucine, reported conversion times
for preb-1 to a-HDL of 15 min, rapid back-conversion of
a2 to preb-1 HDL, and a plasma residence time for
preb-1 of approximately 4 days (45). However, the tracer
enrichments for preb-1 and a-HDL appeared in plasma at
the same time and had parallel time curves. Because the
tracer technique did not provide disappearance curves
for preb-1 and a-HDL, the parallel time curves for tracer
appearance of apoA-I in preb-1 and a-HDL could just as
well be interpreted as independent pools with different
residence times. There is an unfortunate paucity of data
on kinetics of preb-1 HDL in humans.
TABLE 2. Effect of selective HDL delipidation on aortic atheroma in monkeys
Total atheroma volume Percent atheroma volume
Pretreatment Posttreatment % change Pretreatment Posttreatment % Change
Mean 5.63 5.25 26.9% 31.78 30.26 24.4%
SD 1.27 1.41 11.1% 4.41 5.61 14.8%
P 5 0.03 P 5 0.13
N 5 13 lesions, matched on pre- and posttreament Intravascular ultrasound (IVUS) studies, in six monkeys.
Total atheroma volume 5 mm3/mm lesion length. Percent atheroma volume 5 %.
Fig. 8. A: Preb-1 and a HDL apoA-I plasma mass (pool size) in vervets at baseline and immediately after infusion of selectively delipidated
vervet plasma (mean 6 SEM of five vervets) B: Modeling fitting of preb-1 and a-HDL apoA-I mass after infusion. Symbols are the masses of
apoAI in each HDL type. Lines are fitted curves to the data determined by kinetic modeling using the model in Fig. 2. Mean of five vervets.
“Preb-1” includes preb-x as shown in Fig. 5.
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Infusion of selectively delipidated monkey plasma tended
to improve aortic atherosclerosis in monkeys that had devel-
oped atherosclerosis on a high saturated fat diet for 7 years.
This finding is consistent with a human trial of apoA-I Milano
in coronary atherosclerosis (33), and several animal mod-
els of atherosclerosis in which complexes of apoA-I and
phospholipid similar to preb-1 HDL were given intrave-
nously (29–32). A strength of this study includes its use of
an amount of apoA-I and several infusions that are suitable
for scaling-up for human studies. The strictly blinded pro-
tocol for identifying aortic lesions provided an unbiased
identification and analysis of lesions. Infusion of preb-1
HDL would be expected to directly reduce atheroma vol-
ume, the endpoint that significantly improved. Percent
atheroma volume tended to decrease although not signifi-
cantly. Percent atheroma volume is related to remodeling
of plaque as much as to reduction in volume, and may be
viewed as a second-order effect of the reduction in ather-
oma volume itself. Limitations include the absence of a con-
trol group of monkeys receiving a sham infusion and the
small number of monkeys that had discrete aortic lesions
visualized on pre- and posttreatment IVUS studies. This is
the first study to our knowledge to use IVUS to study aortic
atherosclerosis in monkeys. Because all of the monkeys had
aortic atherosclerosis on histological analysis, it is likely that
the technique of IVUS utilized in this study was not optimal
for this purpose.
In conclusion, selective delipidation of HDL in human
or monkey plasma generates cholesterol-depleted HDL,
resembling preb-1 and small a species that are active in re-
moving cholesterol from cells. Infusion into monkeys of
selectively delipidated monkey plasma containing these
small HDL rapidly converts them to larger a-2 and a-1
HDL during the first day, and more slowly for at least an-
other day, suggesting the possibility that selective delipid-
ation induces a more active process of reverse cholesterol
transport lasting 2 days or more. The IVUS results, suggest-
ing that the treatment improved aortic atherosclerosis in
the monkeys, support the clinical significance of the HDL
kinetic results. Thus, selective HDL delipidation has poten-
tial as a therapy for atherosclerosis, and a Phase 1 pilot trial
has been completed in patients with CHD. Potential ther-
apeutic applications for selective HDL delipidation also
include acute coronary syndrome, acute stroke (46), coro-
nary ischemia-reperfusion injury (47, 48), and in-stent
stenosis (49).
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